| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18235 R76477 |
Laspro, 2024 | Oral clefts (ICD 10 codes Q35 or Q36 or Q37) | during pregnancy (anytime or not specified) excluded | nested case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
1.34 [1.19;1.51] excluded (exposition period) |
269/- 11,829/- | 12,098 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7469 R22224 |
Anderson, 2020 | Any oral cleft | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.07 [0.71;1.59] | -/- 0/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7354 R21611 |
Jordan, 2016 | Oro‐facial clefts | 3 months or more before pregnancy or1st trimester excluded | retrospective cohort (registry) | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
0.45 [0.11;1.81] C excluded (exposition period) |
2/2,601 861/506,155 | 863 | 2,601 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5882 R14695 |
Ban (Controls unexposed, disease free), 2014 | Orofacialcleft | 1st trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 1.64 [0.78;3.45] | -/3,189 438/325,294 | - | 3,189 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6016 R15541 |
Jimenez-Solem (Controls unexposed, NOS), 2012 | Oro-facial clefts | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.76 [0.11;5.40] | 1/928 -/843,797 | - | 928 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.16 [0.82;1.65] | 0 | 4,117 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, disease free; 2: Controls unexposed, NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded